购物车
- 全部删除
- 您的购物车当前为空
Evodenoson (ATL313) 是一种有效的选择性腺苷 A2a 受体(A2aR)激动剂,可用于治疗眼部疾病、肿瘤和免疫系统疾病,可用于研究开角型青光眼和血液肿瘤。
为众多的药物研发团队赋能,
让新药发现更简单!
Evodenoson (ATL313) 是一种有效的选择性腺苷 A2a 受体(A2aR)激动剂,可用于治疗眼部疾病、肿瘤和免疫系统疾病,可用于研究开角型青光眼和血液肿瘤。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,750 | 现货 | |
5 mg | ¥ 4,420 | 现货 | |
10 mg | ¥ 6,640 | 现货 | |
25 mg | ¥ 12,800 | 现货 | |
50 mg | ¥ 17,190 | 现货 | |
100 mg | ¥ 25,500 | 现货 |
产品描述 | Evodenoson (ATL313) is a potent and selective adenosine A2a receptor (A2aR) agonist for the treatment of eye diseases, tumors, and immune system disorders, and may be used in studies of open-angle glaucoma and blood tumors. |
体内活性 | The rats were divided into 3 groups: Group 1 received a continuous intravenous infusion of saline given 10 min prior to ischemia and throughout reperfusion (n=8); Group 2 received a continuous intravenous infusion of 10 ng/kg/min of ATL 313 given 10 min prior to ischemia and throughout reperfusion (n=8); and group 3 received an intravenous bolus of ATL 313 (900 ng/Kg body weight) given 10 min prior to ischemia, and continuous intravenous infusion of 10 ng/kg/min of ATL 313 started at 20 min after ischemia and throughout reperfusion (n=8). After the euthanasia of the rats, the hearts were harvested for the assessment of the risk zone and zone of necrosis of the left ventricle. Conclusion: A(2A)AR agonist ATL 313 significantly reduced infarct size and improved LV contractility at the end of reperfusion assessed by LV dp/dt at a dose of 900 ng/Kg. The mechanisms for the observed cardioprotection effect of ATL 313 remain to be determined.[2] |
别名 | DE 112, DE-112, ATL 313, DE112, ATL313, 依沃迪松, ATL-313 |
分子量 | 499.52 |
分子式 | C23H29N7O6 |
CAS No. | 844873-47-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (100.1 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.